Tag Archive for: docetaxel

Preliminary Data From a Phase 1/2 Trial of PDS01ADC Plus Docetaxel in mCRPC

/in , , , /by

Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC  (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]

Read more

Docetaxel Rechallenge vs Cabazitaxel in mCRPC: VA Cohort Study

/in /by

A retrospective cohort study published January 2, 2026, in JAMA Network Open compared docetaxel rechallenge to cabazitaxel in 669 patients with metastatic castration-resistant prostate cancer treated in the Veterans Affairs healthcare system from 2010 to 2023. All patients had received at least three cycles of initial docetaxel without disease progression and then one intervening systemic […]

Read more

A Phase 3 Study of Pasritamig Plus Docetaxel

/in , , /by

Pasritamig is a bispecific T-cell engager that targets human kallikrein 2 (KLK2), a protein found primarily in prostate tissue and often retained in advanced prostate cancer. This drug brings T cells into close contact with KLK2-expressing tumor cells, directing immune responses against the cancer. In phase 1 studies, pasritamig was evaluated in men with metastatic […]

Read more

ARASAFE Trial Offers Safer Docetaxel-Darolutamide-ADT Regimen for mHSPC

/in , , /by

Recent data presented at the 2025 European Society for Medical Oncology (ESMO) Congress reveal a promising new treatment schedule for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 ARASAFE trial evaluated an alternative docetaxel dosing regimen combined with darolutamide and androgen deprivation therapy (ADT), showing significant reductions in severe toxicities while maintaining effective […]

Read more

PSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial

/in /by
Read more